OncXerna Begins Navicixizumab Phase II Basket Trial
In the signal-finding study currently enrolling colorectal and triple-negative breast cancer patients, the company will also evaluate the ability of its Xerna TME Panel to identify best responders.
Lauran Benjamin Paul Oberstein Mereo Biopharma Genentech Avastin Drug Administration Perlmutter Cancer Center
Source: precisiononcologynews.com